AVeta Medical
Private Company
Funding information not available
Overview
AVeta Medical is a clinical-stage medical device company targeting the vast, underserved market of genitourinary syndrome of menopause (GSM). Its lead product is a novel, non-hormonal device designed to stimulate the body's natural wound-healing processes to restore vaginal tissue moisture and health, offering immediate and long-lasting symptom relief. The company has secured significant non-dilutive funding, including a €2.5M EIC Accelerator grant, and is progressing through clinical development with a First-in-Human trial underway and FDA/CE regulatory pathways in sight. AVeta aims to address a condition affecting hundreds of millions of women globally, where current hormonal treatments are often avoided or contraindicated.
Technology Platform
A medical device based on wound-healing science, designed to stimulate the body's natural healing response to restore moisture and health to vaginal tissue without hormones or pharmaceuticals.
Opportunities
Risk Factors
Competitive Landscape
The primary competition is the current standard of care: hormonal treatments like vaginal estrogen. AVeta's device differentiates by being non-hormonal, which is critical for contraindicated patients (e.g., breast cancer survivors). It may also compete with other non-hormonal devices and energy-based therapies (e.g., lasers), positioning itself on safety, affordability, and a natural healing mechanism.